scPharmaceuticals announced the pricing of an underwritten public offering of 12M shares of its common stock at a public offering price of $4.00 per share. All of the shares are being offered by scPharmaceuticals. Leerink Partners and TD Cowen are acting as joint book-running managers for the offering. Craig-Hallum is acting as lead manager, Maxim is acting as manager. H.C. Wainwright & Co. is acting as a financial advisor.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SCPH:
- scPharmaceuticals Announces Pricing of $50.0 Million Public Offering
- scPharmaceuticals Secures Funding, Advances FUROSCIX Commercialization
- scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the FUROSCIX Indication in Heart Failure
- scPharmaceuticals Announces Non-Dilutive Financings Totaling Up to $125 Million with Perceptive Advisors
- scPharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants